Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
- Conditions
- Pancreatic CancerMelanomaSquamous Cell Carcinoma of the Head and NeckProstate Cancer
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03098160
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: TH-302 combination with pemetrexedDrug: Matched placebo in combination with pemetrexed
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 265
- Registration Number
- NCT02093962
- Locations
- 🇺🇸
Research Medical Center, Kansas City, Kansas, United States
🇺🇸St. Joseph Mercy Ann Arbor Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 19
- Registration Number
- NCT02047500
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02020226
- Locations
- 🇺🇸
Yuma Regional Cancer Center, Yuma, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 11
- Registration Number
- NCT01864538
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Conditions
- Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 693
- Registration Number
- NCT01746979
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact Merck Communication Center, Darmstadt, Germany
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT01522872
- Locations
- 🇺🇸
Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 640
- Registration Number
- NCT01440088
- Locations
- 🇺🇸
Oncology Specialists, Park Ridge, Illinois, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Mayo Arizona, Scottsdale, Arizona, United States
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
- Conditions
- Advanced Renal Cell CarcinomaGastrointestinal Stromal TumorsPancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01381822
- Locations
- 🇺🇸
IU Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
- Conditions
- Chronic Lymphocytic LeukemiaAdvanced MyelofibrosisAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaHigh-risk Myelodysplastic Syndrome
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01149915
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States